Last reviewed · How we verify
KPS-0373
KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.
KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | KPS-0373 |
|---|---|
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (Sodium-Glucose Cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, allowing excess glucose to be excreted in urine. This mechanism lowers blood glucose levels independently of insulin secretion and has been associated with additional cardiovascular and renal protective effects in diabetic patients.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
Key clinical trials
- Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration (PHASE3)
- An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE2)
- A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KPS-0373 CI brief — competitive landscape report
- KPS-0373 updates RSS · CI watch RSS
- Kissei Pharmaceutical Co., Ltd. portfolio CI